astellas
Leading Light for Life

News Release

April 27, 2007

Astellas Receives an European Commission Approval for Advagraf®

Japan, April 27, 2007 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, "Astellas") today announced that Astellas's European subsidiary has received an European Commission approval for the immunosuppressant, Advagraf (generic name: tacrolimus, prolonged release capsules) on April 25, 2007 (local time).

Astellas's European subsidiary has submitted a Marketing Authorization Application (MAA) under centralized procedure to the European Medicines Agency (EMEA) for Advagraf. The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to grant the marketing authorization for Advagraf on February 22, 2007, and following this positive opinion, the European Commission has approved Advagraf this time. The indication for Advagraf is: "Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients."
Astellas's European subsidiaries plan to launch Advagraf in the UK and Germany in June, and other countries will follow one after another.

Advagraf is a once-daily formulation of Astellas's Prograf (tacrolimus, twice-daily formulation), a leading immunosuppressive agent marketed in over 70 countries around the world for prevention of organ rejection in transplantation. Advagraf is expected to contribute to reduce grafts-loss for longer period with higher degree by improving compliance to reduce dosing from twice-daily to once-daily.

#######

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com